Barbara Adamo

Medical Adjunct part-time

ORCID: 0000-0001-7129-8156
Knowledge area: Medicina

Contact Information
Department of Medicine
C/Villarroel, 136

adamo(a)ub.edu

Teaching imparted (current)

Màster en Biomedicina (Universitat de Barcelona): - Biomedicina - Universidad de Barcelona.
Curs Patologia Nutricional, Master Nutrició i malaties cróniques (Universitat de Barcelona) - Innovació i Emprenedoria en Nutrició, Malalties Cròniques i Envelliment Saludable - Universidad de Barcelona.
Oncologia Mèdica i Radioteràpica - Medicina - Universidad de Barcelona.
Master Universitario de Patología Mamaria-Senología - Patologia Mamaria-Senologia - Universidad de Barcelona.

Academic training

LLICENCIATURA EN MEDICINA . Universitat de Messina. Messina, Itàlia. . 2003 . (Diploma / Degree / Activities)
PhD Program in Clinical Oncology . Universitat de Messina . 2011 . (Ph.D.)
Especialització en Oncologia Mèdica . Departament d'Oncologia Mèdica. Hospital Policlinico G. Martino, Universidad de Messina. Itàlia. . 2007 . (Specialized Training)

Professional experience

Oncologia Mèdica a la Unitat de Fases 1. Vall d'Hebron Institut d'Oncologia (VHIO). Hospital Universitari de la Vall d'Hebron. 09/2012 - 05/2014
Oncologia Mèdica a la Unitat de Càncer de Mama. Hospital Clínic de Barcelona. 05/2014
Professora associada. Universitat de Barcelona. 2019

Research Projects

Estudio de fase II, multicéntrico, aleatorizado, abierto, de tres grupos, de LAG525 administrado en combinación con spartallizumab (PDE001), o con . 2019 - 2019 . Ref.2017-004865-28 . Novartis Farmacéutica, S.A . PI: Barbara Adamo
"A Phase 3, Open-Label, randomized, Parallel, 2-Arm, Multi-Center Study of Talazoparib (BMN 673) versus Physicians's Choice in Germline BRCA . 2019 - 2019 . Ref.HCB/16/644 . FUNDACIÓN GRUPO ESPAÑOL DE INVESTIGACIÓN EN CANCER DE MAMA (GEICAM) . PI: Barbara Adamo
A phase II, Multi center study of BGB324 in combination with Pembrolizumab in patients with Previously treated, locally advanced and . 2019 - 2019 . Ref.HCB/17/232 . INC Research UK Ltd. . PI: Barbara Adamo
LUCY - Lynparza Breast cancer real world utility, clinical effectiveness and safety study. A phase IIIb, single-arm, open-label multicentre study of . 2019 - 2019 . Ref.HCB/17/704 . PAREXEL Global Operations Ireland . PI: Barbara Adamo
Caracterizacion de los linfocitos T CD8+/PD1+ en cancer de mama avanzado receptor hormonal-positivo con un fenotivo agresivo HER2-enriched . 2019 - 2021 . Ref.19-IO-011 . Fundación Merck Salud . PI: Aleix Prat Aparicio

Journal Publications

Martinez-Saez, Olga; Chic, Nuria; Pascual, Tomas; Adamo, Barbara; Vidal, Maria; Gonzalez-Farre, Blanca; Sanfeliu, Esther; Schettini, Francesco; Conte, Benedetta; Braso-Maristany, Fara; Rodriguez, Adela; Martinez, Debora; Galvan, Patricia; Rodriguez, Ana Belen; Martinez, Antonio; Munoz, Montserrat; Prat, Aleix (2020). Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Research, 22(1), p. 45 . Institutional Repository . ISSN: 1465-5411
Adamo, Barbara; Bellet, Meritxell; Pare, Laia; Pascual, Tomas; Vidal, Maria; Perez Fidalgo, Jose A.; Blanch, Salvador; Martinez, Noelia; Murillo, Laura; Gomez-Pardo, Patricia; Lopez-Gonzalez, Ana; Amillano, Kepa; Canes, Jordi; Galvan, Patricia; Gonzalez-Farre, Blanca; Gonzalez, Xavier; Villagrasa, Patricia; Ciruelos, Eva; Prat, Aleix (2019). Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. Breast Cancer Research, 21(1) . Institutional Repository . ISSN: 1465-5411
Aleix Prat; Valentina Guarneri; Laia Paré; Gaia Griguolo; Tomás Pascual; Maria V Diec;, Núria Chic; Blanca González-Farré; Antonio Frassoldati; Esther Sanfeliu; Juan M Cejalvo; Montserrat Muñoz; Giancarlo Bisagni; Fara Brasó-Maristany; Loredana Urso; Maria Vidal; Alba A Brandes; Barbara Adamo; Antonino Musolino; Federica Miglietta; Benedetta Conte; Mafalda Oliveira; Cristina Saura; Sònia Pernas; Jesús Alarcón; Antonio Llombart-Cussac; Javier Cortés; Luis Manso; Rafael López; Eva Ciruelos; Francesco Schettini; Patricia Villagrasa; Lisa A Carey; Charles M Perou; Federico Piacentini; Roberto D'Amico: Enrico Tagliafico; Joel S Parker; Pierfranco Conte. (2020). A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. The Lancet Oncology, 21(11), pp. 1455 - 1464 . https://doi.org/10.1016/S1470-2045(20)30450-2 . ISSN: 1470-2045
Aleix Prat, Yi-Hsuan Tsai, Tomás Pascual, Laia Paré, Barbara Adamo, Maria Vidal, Fara Brasó-Maristany, Patricia Galván, Jan C. Brase, Vanessa Rodrik-Outmezguine, Stephen R.D. Johnston, Eva M Ciruelos and Joel S. Parker. (2020). A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer. Clinical Cancer Research . https://doi.org/10.1158/1078-0432.CCR-20-2793 . ISSN: 1078-0432
Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cortés J, Rexer B, Paré L, Forero A, Wolff AC, Morales S, Adamo B, Brasó-Maristany F, Vidal M, Veeraraghavan J, Krop I, Galván P, Pavlick AC, Bermejo B, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, Hilsenbeck SG, Oliveira M, Dieci MV, Griguolo G, Fasani R, Nuciforo P, Parker JS, Conte P, Schiff R, Guarneri V, Osborne CK, Rimawi MF (2019). HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade. JNCI: Journal of The National Cancer Institute . https://doi.org/10.1093/jnci/djz042 . ISSN: 0027-8874
Adamo B; Rita Ricciardi GR; Ieni A; Franchina T; Fazzari C; Sanò MV; Angelico G; Michele C; Tuccari G; Adamo V. (2017). The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer. Oncotarget, 8(44), pp. 76974 - 76986 . https://doi.org/10.18632/oncotarget.20293 . ISSN: 1949-2553
Adamo B; Ricciardi GRR; Ieni A; Franchina T; Fazzari C; Sanò MV; Angelico G; Caruso M; Tuccari G; Adamo V. (2019). The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer. Oncotarget, 10(8), p. 917 . https://doi.org/10.18632/oncotarget.26650 . ISSN: 1949-2553
Aleix Prat; Francesco Schettini; Nuria Chic; Fara Brasó-Maristany; Laia Paré Brunet; Tomás Pascual; Benedetta Conte; Olga Martínez-Sáez; Adamo B; Maria Vidal; Aranzazu Fernández-Martinez; Blanca González-Farre; Esther Sanfeliu; Juan Cejalvo; Giuseppe Perrone; Giovanna Sabarese; Francesca Zalfa; Patricia Villagrasa; Joaquín Gavilá; Carlos Barrios; Ana Lluch; Miguel Martin; Sabino De Placido; Esther Barnadas; Mariavittoria Locci; Vicente Peg; Roberta Fasani. (2021). Clinical, pathological and PAM50 gene expression features of HER2-low breast cancer. npj Breast Cancer, 7 . Institutional Repository . ISSN: 2374-4677
Pascual T; Fernandez-Martinez A; Tanioka M; Dieci MV; Pernas S; Gavilá J; Guarneri V; Cortés J; Villagrasa P; Chic N; Vidal M; Adamo B; Muñoz M; Griguolo G; Llombart-Cussac A; Conte P; Oliveira M; Conte B; Paré L; Galván P; Carey LA; Perou CM; Prat A; (2021). Independent validation of the PAM50-based Chemo-Endocrine Score in hormonal receptor positive HER2-positive breast cancer treated with neoadjuvant therapy. Clinical Cancer Research . https://doi.org/10.1158/1078-0432.CCR-20-4102 . ISSN: 1078-0432

Other publications

M. Muñoz Mateu; B. Adamo; A. Arance Fernández;, J. M. Borràs André;, L. Gaba García; JJ Grau de Castro; J Maurel Santasusana; B Mellado González; A Prat Aparicio; N. Reguart Aransay; T. Saurí Nadal; A. Tuca Rodríguez; M. Vidal Losada; N Viñolas Segarra. (2020). Sección VIII Oncología médica . In Medicina Interna . Farreras-Rozman . ISBN: 9788491135456 . https://bit.ly/39gzMT7